Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia.
Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia.
Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens Laiko, Athens, Greece.
Department of Internal Medicine and Clinical Immunology, AP HP Hôpital La Pitié-Salpêtrière, Paris, France.
CNRS UMR 7087, INSERM UMR S-959, DHU I2B, Sorbonne Université, Paris, France.
Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Essen University Hospital, Essen, Germany.
Center for Outcomes Research in Liver Disease, Washington D.C.
Department of Hygiene, Epidemiology and Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Hepatitis B and C Public Policy Association, L-2453 , Luxembourg.
Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon- and ribavirin-free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient-reported outcomes and is cost-saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. With the introduction of the interferon-free all-oral, once a day pill treatment regimen for the cure of HCV, the potential to eliminate HCV by 2030 has become a possibility for some regions of the world. Nevertheless, there are barriers to screening, linkage to care, and treatment in many countries that must be overcome in order to reach this goal. In conclusion, globally, work must continue to ensure national policies are in place to support screening, linkage to care and affordable treatment in order to eliminate HCV.